Next-Generation Biomanufacturing Market Size Forecasted to be Worth USD 39.18 Billion in 2028

Next-Generation Biomanufacturing Market Size

The global next-generation biomanufacturing market size is expected to reach USD 39.18 Billion in 2028 at a CAGR of 9.9% during the forecast period. Increasing use of biomanufacturing to meet growing demand for efficient biomaterials that can be added to medicine, food & beverage sector, and industrial applications is a key factor driving revenue growth of the market. Next-generation biomanufacturing processes enables scalable production of biomaterials used for biological medicines that are used in treatment of critical health conditions such as liver and kidney disorders, diabetes, and cancer. Rising use of single-use products such as single-use bioreactors, biocontainers, and increasing funding from government and private organizations for development of next-generation biomanufacturing units and facilities are some other key factors expected to drive market growth over the forecast period.

Next-generation biomanufacturing process leverage advanced technologies such as artificial intelligence, machine learning, and augmented reality, among others. Incorporation of these technologies offer seamless, efficient, and high-quality outcomes as compared to first-generation process. Biopharmaceutical companies and research institutes are increasingly adopting next-generation biomanufacturing processes as they are energy-efficient, require minimal water, generate less volume solid waste, and result in significantly lower carbon emissions. In addition, deployment of advanced technologies during manufacturing processes enable value-addition and efficient product quality testing, maintenance, and storage. Furthermore, increasing demand for gene-therapy and cell-based products and rising investment by government to develop water and energy efficient next-generation bioprocessing units are key factors expected to further fuel revenue growth of market.

Next-Generation Biomanufacturing

Next-Generation Biomanufacturing

Grab Your Free Sample PDF Copy Now

Some Key Highlights in the Report:

  • Biopharmaceutical companies segment accounted for largest revenue share of 39% in the global market in 2020. This can be attributed to rapid technological development and advancements and rising investment from private organizations and government bodies to develop energy efficient next-generation bioprocessing units.
  • North America accounted for largest revenue share in the global market in 2020 among all the other regional segments and is expected to register significant revenue growth over the forecast period. Growth can be attributed to increasing incorporation of advanced technologies in manufacturing facilities, increasing research and development activities, availability of state-of-the-art biological research infrastructure, and robust presence of prominent biotechnology and pharmaceutical companies in the region.
  • Major companies operating in the market include Merck KGaA, Thermo Fisher Scientific Inc., Eppendorf AG, Danaher Corporation, GEA Group, Sartorius AG, bbi-biotech GmbH, Solaris Biotechnology Srl, Esco Group of Companies, Pierre Guérin, and PBS Biotech, Inc.
  • In April 2020, Akron Biotech expanded its operations through acquisition of Cambryn Biologics’ biologics facility in Sarasota, Florida. The addition of biomanufacturing plant to its portfolio is expected to enable Akron Biotech to cater to increasing demand for the company’s cytokine and media products from the rapidly developing cell and gene therapy industry.
  • In March 2021, Pharmaron Beijing entered into a definitive agreement for the acquisition of a biomanufacturing site, Allergen Biologics Limited, in the U.K. from ABbVie in a deal valued at USD 118.7 Million. Through the acquisition, Pharmaron will continue to develop integrated capabilities platforms for cell and gene therapy.

For the purpose of this report, Emergen Research has segmented the global next-generation biomanufacturing market based on type, application, end-use, and region as follows:

Type Outlook (Revenue, USD Billion; 2018–-2028)

  • Continuous Upstream Biomanufacturing
  • Single-Use Upstream Biomanufacturing
  • Downstream Biomanufacturing

Application Outlook (Revenue, USD Billion; 2018–-2028)

  • Monoclonal Antibodies
  • Hormones
  • Vaccines
  • Recombinant Proteins
  • Others

End-Use Outlook (Revenue, USD Billion; 2018–-2028)

  • Biopharmaceutical Companies
  • Research Institutions
  • CMOs/CDMOs

Regional Outlook (Revenue, USD Billion; 2018–-2028)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • U.A.E.
    • Israel
    • Turkey
    • Rest of MEA

To get leading market solutions, visit the link below:

To Top

Pin It on Pinterest

Share This